Adding immunotherapy and targeted therapy to chemotherapy for early breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether adding two newer drugs to standard chemotherapy can improve outcomes for women with early-stage breast cancer that is hormone-receptor positive and has low HER2. The goal is to see if a combination of immunotherapy and targeted therapy helps shrink tumors before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have early-stage breast cancer (tumor size up to a certain limit) that has spread only to nearby lymph nodes, not distant organs.
- Your tumor must be hormone receptor positive (HR+) and HER2 low — this means your cancer cells have low amounts of the HER2 protein.
- Your PD-L1 status must be known or you must provide a tissue sample for testing before starting.
- You need to be in generally good health (able to do light activities) and have normal organ function.
- If you are female and premenopausal, you must agree to use effective birth control or avoid sex during and for at least 7 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SHR-A1811) alone or with another drug (adebrelimab) before surgery for women with a specific type of early-stage breast cancer called HR+, HER2-low. The goal is to see if this combination can shrink the tumor before surgery, possibly leading to better outcomes.
This trial tests a combination of two targeted drugs (SHR-A1811 and pertuzumab) given before surgery to shrink HER2-positive breast cancer. It aims to see if this approach improves outcomes for patients with early-stage but high-risk disease.
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests adding a drug called adebrelimab to standard chemotherapy and possibly radiation, given before surgery for breast cancer that is HER2-negative and locally advanced. The goal is to see if this combination helps shrink tumors more effectively, potentially allowing for breast-conserving surgery.
This trial tests a new drug combined with other anti-cancer drugs for advanced breast cancer. The goal is to see if the combination can shrink tumors and help people live longer, and if it is safe.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
Hear when a new Breast Cancer Early Stage Breast Cancer (Stage 1-3) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.